Home / CCL5/RANTES / Recombinant Human CCL5/Met-RANTES Protein

Recombinant Human CCL5/Met-RANTES Protein

Catalog #: 335-RM
7 Citations Datasheet

Carrier Free

Catalog # Availability Size / Price Qty
335-RM-025/CF

With Carrier

Catalog # Availability Size / Price Qty
335-RM-025
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (7)
FAQs
Reviews
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human CCL5/Met-RANTES Protein Summary

Product Specifications

Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with human CCR5. The ED50 for this effect is 0.02-0.1 µg/mL. Measured by its ability to chemoattract 2-day cultured human monocytes. Schall, T. et al. (1990) Nature 347:669. The ED50 for this effect is 0.4-1.2 µg/mL.
Source
E. coli-derived human CCL5/RANTES protein
Ser24-Ser91, with an N-terminal Met
Accession #
P13501
N-terminal Sequence
Analysis
Met
Predicted Molecular Mass
7.8 kDa

Product Datasheets

You must select a language.

x

335-RM (with carrier)

Product Datasheet

You must select a language.

x

335-RM/CF (carrier free)

Product Datasheet

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

335-RM

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

335-RM/CF

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CCL5/RANTES

CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta -chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1 - 3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature human CCL5 shares 75% - 84% aa sequence identity with canine, cotton rat, feline, mouse, and rat CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11 - 13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14 - 16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17). The Met-RANTES preparation from R&D Systems has been shown to be a partial agonist in monocyte chemotactic assays, exhibiting an ED50 10 - 20 fold higher than that of recombinant RANTES.

References
  1. Schall, T.J. et al. (1990) Nature 347:669.
  2. Bacon, K.B. et al. (1995) Science 269:1727.
  3. Fischer, F.R. et al. (2001) J. Immunol. 167:1637.
  4. Schall, T.J. et al. (1992) Eur. J. Immunol. 22:1477.
  5. Schall, T.J. et al. (1988) J. Immunol. 141:1018.
  6. Appay, V. and S.L. Rowland-Jones (2001) Trends Immunol. 22:83.
  7. Levy, J.A. (2009) J. Immunol. 182:3945.
  8. Randolph-Habecker, J.R. et al. (2002) Cytokine 19:37.
  9. DeVico, A.L. and Gallo, R.C. (2004) Nat. Rev. Microbiol. 2:401.
  10. Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
  11. Appay, V. et al. (1999) J. Biol. Chem. 274:27505.
  12. Proudfoot, A.E.I. et al. (2003) Proc. Natl. Acad. Sci. 100:1885.
  13. von Hundelshausen, P. et al. (2005) Blood 105:924.
  14. von Hundelshausen, P. et al. (2001) Circulation 103:1772.
  15. Zernecke, A. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1897.
  16. Baltus, T. et al. (2003) Blood 102:1985.
  17. Soria, G. and A. Ben-Baruch (2008) Cancer Lett. 267:271.
Entrez Gene IDs
6352 (Human); 20304 (Mouse); 403522 (Canine); 493689 (Feline)
Alternate Names
CCL5; chemokine (C-C motif) ligand 5; D17S136Enormally T-expressed, and presumably secreted; EoCP; Eosinophil chemotactic cytokine; RANTES; SISd; SIS-delta; small inducible cytokine A5 (RANTES); small inducible cytokine subfamily A (Cys-Cys), member 5; Small-inducible cytokine A5; T cell-specific protein P228; T-cell specific protein p288; TCP228T-cell-specific protein RANTES

Citations for Recombinant Human CCL5/Met-RANTES Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

7 Citations: Showing 1 - 7
Filter your results:

Filter by:

  1. Kupffer Cells and Blood Monocytes Orchestrate the Clearance of Iron-Carbohydrate Nanoparticles from Serum
    Authors: T Arsiwala, AS Vogt, AE Barton, V Manolova, F Funk, B Flühmann, MF Bachmann
    International Journal of Molecular Sciences, 2022-02-28;23(5):.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  2. Cancer-associated fibroblast-derived CCL5 contributes to cisplatin resistance in A549 NSCLC cells partially through upregulation of lncRNA HOTAIR expression
    Authors: X Sun, Z Chen
    Oncology Letters, 2021-08-02;22(4):696.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Regulation of the terminal maturation of iNKT cells by mediator complex subunit 23
    Authors: Y Xu, Y Sun, H Shen, Y Dai, H Liu, R Li, H Zhang, L Wu, X Zhu, X Liu
    Nat Commun, 2018-09-24;9(1):3875.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  4. Brcal Defective Breast Cancer Cells Induce in vitro Transformation of Cancer Associated Fibroblasts (CAFs) to Metastasis Associated Fibroblasts (MAF)
    Authors: SK Hemalatha, SK Sengodan, R Nadhan, J Dev, RR Sushama, V Somasundar, R Thankappan, A Rajan, NR Latha, GR Varghese, AP Mathew, T Somanathan, P Srinivas
    Sci Rep, 2018-09-17;8(1):13903.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. CCL5/RANTES contributes to hypothalamic insulin signaling for systemic insulin responsiveness through CCR5
    Sci Rep, 2016-11-29;6(0):37659.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  6. Activation of an innate immune receptor, Nod1, accelerates atherogenesis in Apoe-/- mice.
    Authors: Kanno S, Nishio H, Tanaka T, Motomura Y, Murata K, Ihara K, Onimaru M, Yamasaki S, Kono H, Sueishi K, Hara T
    J Immunol, 2014-12-08;194(2):773-80.
    Species: Mouse
    Sample Types: In Vivo
  7. Peritoneal Administration of Met-RANTES Attenuates Inflammatory and Nociceptive Responses in a Murine Neuropathic Pain Model.
    Authors: Liou J, Mao C, Ching-Wah Sum D, Liu F, Lai Y, Li J, Day Y
    J Pain, 2012-11-23;14(1):24-35.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human CCL5/Met-RANTES Protein

There are currently no reviews for this product. Be the first to review Recombinant Human CCL5/Met-RANTES Protein and earn rewards!

Have you used Recombinant Human CCL5/Met-RANTES Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review